MX9804459A - Procedimiento para el diagnostico y terapia de epitelioma. - Google Patents

Procedimiento para el diagnostico y terapia de epitelioma.

Info

Publication number
MX9804459A
MX9804459A MX9804459A MX9804459A MX9804459A MX 9804459 A MX9804459 A MX 9804459A MX 9804459 A MX9804459 A MX 9804459A MX 9804459 A MX9804459 A MX 9804459A MX 9804459 A MX9804459 A MX 9804459A
Authority
MX
Mexico
Prior art keywords
epithelioma
diagnosing
treating
vff
gene
Prior art date
Application number
MX9804459A
Other languages
English (en)
Inventor
Karl-Heinz Heider
Gunther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Original Assignee
Boehringer Ingelheim Int
Karlsruhe Forschzent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Boehringer Ingelheim Int, Karlsruhe Forschzent filed Critical Boehringer Ingelheim Int
Publication of MX9804459A publication Critical patent/MX9804459A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invencion se refiere a un procedimiento para el diagnostico y la terapia de epitelioma, que se basa en la expresion del exon variante v6 del gen CD44, como blanco u objetivo molecular. En una forma de realizacion preferida, se utilizan moléculas de anticuerpos específicos a v6, en especial el anticuerpo monoclonal BIWA-1- (VFF-18).
MX9804459A 1995-12-06 1998-06-04 Procedimiento para el diagnostico y terapia de epitelioma. MX9804459A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17

Publications (1)

Publication Number Publication Date
MX9804459A true MX9804459A (es) 1998-09-30

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9804459A MX9804459A (es) 1995-12-06 1998-06-04 Procedimiento para el diagnostico y terapia de epitelioma.

Country Status (26)

Country Link
EP (1) EP0865609B1 (es)
JP (1) JP2000502067A (es)
KR (1) KR100473824B1 (es)
CN (1) CN1151377C (es)
AR (1) AR004360A1 (es)
AT (1) ATE235056T1 (es)
AU (1) AU726704B2 (es)
BG (1) BG62985B1 (es)
BR (1) BR9611901A (es)
CA (1) CA2239709A1 (es)
CO (1) CO4520233A1 (es)
CZ (1) CZ174198A3 (es)
DE (1) DE59610248D1 (es)
DK (1) DK0865609T3 (es)
EE (1) EE03783B1 (es)
ES (1) ES2190484T3 (es)
HK (1) HK1011560A1 (es)
MX (1) MX9804459A (es)
NO (1) NO319903B1 (es)
NZ (1) NZ324314A (es)
PL (1) PL184521B1 (es)
PT (1) PT865609E (es)
SK (1) SK284378B6 (es)
TR (1) TR199801027T2 (es)
UY (1) UY24389A1 (es)
WO (1) WO1997021104A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
PE20021098A1 (es) * 2001-05-18 2003-02-11 Boehringer Ingelheim Int ANTICUERPOS ESPECIFICOS DE CD44v6
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
CN102741292B (zh) * 2010-02-04 2015-10-21 霍夫曼-拉罗奇有限公司 在治疗头和颈鳞状细胞癌中使用的cd44单克隆抗体
US9218450B2 (en) 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
WO2019161528A1 (en) * 2018-02-22 2019-08-29 Abmart Shanghai Co., Ltd. Therapeutic antibody and uses thereof
WO2023227644A2 (en) 2022-05-25 2023-11-30 Akiram Therapeutics Ab Binding protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08511419A (ja) * 1993-06-18 1996-12-03 ヤルカネン、シルパ 組成物およびＣＤ４４ｖ６に対するモノクローナル抗体を用いる診断方法
EP0767378A1 (de) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Diagnose und Analyse von Magenkarzinomen
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
ES2190484T3 (es) 2003-08-01
KR19990071952A (ko) 1999-09-27
KR100473824B1 (ko) 2005-09-30
WO1997021104A1 (de) 1997-06-12
JP2000502067A (ja) 2000-02-22
NO982588L (no) 1998-08-05
DE59610248D1 (de) 2003-04-24
EE9800164A (et) 1998-12-15
EE03783B1 (et) 2002-06-17
CN1151377C (zh) 2004-05-26
PL184521B1 (pl) 2002-11-29
CZ174198A3 (cs) 1999-02-17
CN1207811A (zh) 1999-02-10
AR004360A1 (es) 1998-11-04
NO319903B1 (no) 2005-09-26
BG62985B1 (bg) 2000-12-29
PT865609E (pt) 2003-08-29
CO4520233A1 (es) 1997-10-15
NO982588D0 (no) 1998-06-05
ATE235056T1 (de) 2003-04-15
DK0865609T3 (da) 2003-06-23
UY24389A1 (es) 2001-10-25
AU726704B2 (en) 2000-11-16
BG102513A (en) 1999-02-26
PL327066A1 (en) 1998-11-23
SK284378B6 (sk) 2005-02-04
HK1011560A1 (en) 1999-07-16
SK73698A3 (en) 1999-01-11
NZ324314A (en) 2000-02-28
TR199801027T2 (xx) 1998-10-21
BR9611901A (pt) 1999-03-02
CA2239709A1 (en) 1997-06-12
EP0865609B1 (de) 2003-03-19
AU1177397A (en) 1997-06-27
EP0865609A1 (de) 1998-09-23

Similar Documents

Publication Publication Date Title
AU5794498A (en) Releasable nonvolatile mass-label molecules
FI965031A (fi) Sieni, jossa AreA-geeni on muunnettu, ja Aspergillus oryzaesta peräisin oleva areA-geeni
HK1011560A1 (en) Method of diagnosing and treating epithelioma
EP1009440A4 (en) METHODS OF INHIBITING RESPONSES ASSOCIATED WITH IMMUNOSTIMULATOR DNA
SE9404250L (sv) Affinitetsseparationsmetod
TR200001313T2 (tr) Protein etkileşimlerini ve fonksiyonel ilişkileri kaydeden tarama sistemleri
EP1255209A3 (en) Apparatus and method for automated protein design
DE69128273D1 (de) Für toxin b von clostridium difficile spezifische monoklonale antikörper
AP9901607A0 (en) Method and apparatus for continuous flow isoelectric focusing for
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
ATE285474T1 (de) Haemophilus adhäsionsproteinen
EP0948512A4 (en) METHOD FOR SYNTHESIZING OLIGONUCLEOTIDES PHOSPHOROTHIOATES
DE69606696D1 (de) Selektives verfahren zur deacylierung von acylverbindungen
ATE284754T1 (de) Biosorbentien für metallionen und verfahren zu ihrer herstellung
WO2002031198A3 (en) Cancer-linked genes as targets for chemotherapy
GB9800378D0 (en) Proteome analysis
DE69534178D1 (en) S?ugetier thymokingene
DE69634448D1 (de) Verbindungen, verfahren und kits zur bildgebung des kardiovaskulären systems und von thromben
ATE305052T1 (de) Drogen untersuchungssystem
GB9726897D0 (en) Process
AU4121997A (en) Method for sorting antifungal molecules acting on the glucanosyltransferase activity
AU4654097A (en) Rdgb-proteins
AU2256197A (en) High affinity nucleic acid ligands of complement system proteins
DK1123396T3 (da) Minimale promotorer og anvendelser deraf
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees